Apr 09, 2024 7:00am EDT ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS
Apr 01, 2024 4:15pm EDT ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights
Jan 22, 2024 7:00am EST ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
Nov 20, 2023 7:00am EST ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease